

## CVC Monthly Meeting

February 25, 2021

11am-12pm PST | 1-2pm CST | 2-3pm EST | 3-4pm AST

No	Description	Notes	Time
1	Welcome and Release Update	<ul style="list-style-type: none"><li>● Planned deployment for February 11th delayed<ul style="list-style-type: none"><li>○ ETA: March 5th</li><li>○ Impacts</li><li>○ Implications for next release</li></ul></li></ul>	10 minutes
2	COVID-19 Terminology Discussion	<ul style="list-style-type: none"><li>● Generic agent - COVID-19 non-replicating viral vector concept with SNOMED International<ul style="list-style-type: none"><li>○ Update from CHI?</li><li>○ Group discussion on path forward</li></ul></li><li>● RFC preparation for Janssen vaccine<ul style="list-style-type: none"><li>○ Thank you Health Canada (Rob Pless, Melanie Reed) for supplying initial product Information!</li><li>○ Placeholder RFC submitted</li><li>○ Any objections to CVC team submitting RFCs without WG consultation or consultation via email going forward?</li></ul></li><li>● COVID-19 Pfizer concept modifications</li><li>● Insight from WG members on any upcoming needs related to the COVID-19 vaccine rollout?<ul style="list-style-type: none"><li>○ Additional product or other concepts to discuss?</li></ul></li></ul>	30 minutes
3	Governance Update	<ul style="list-style-type: none"><li>● Work over the last month has highlighted gaps in CVC capacity to<ul style="list-style-type: none"><li>○ Make medical determinations for concept/product categories</li><li>○ Access early product monograph information to prepare RFCs</li></ul></li><li>● Proposed solution is to assemble an ad-hoc committee of experts from various stakeholder organizations to advise the CVC working group when needed</li><li>● CVC team has begun drafting terms of reference for CVC Working group and a Clinical Advisory Committee</li><li>● Thoughts/feedback on this approach</li></ul>	10 minutes

